

February 10<sup>th</sup>, 2021 PeptiDream Inc. <u>https://www.peptidream.com</u> Ticker Code : 4587 TSE First Section

## PeptiDream Announces the Resignation of Kiichi Kubota from the Board of Directors

KANAGAWA, JAPAN – February 10th, 2021 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company ("PeptiDream")(Tokyo:4587) announces the resignation of Kiichi Kubota, Director and Chairman, from the said position with the expiration of the term of office at the conclusion of the 15<sup>th</sup> Ordinary General Meeting of Shareholders to be held on 25th March, 2021.

 Name of Director
Scheduled Date
Reason for Resignation
Note
Kiichi Kubota, Director and Chairman
March 25, 2021 (the 15<sup>th</sup> Ordinary General Meeting of Shareholders)
Expiration of the term of office
The requirement concerning the number of Directors set forth by laws and company's Articles of Incorporation remains met after Mr. Kubota's resignation.

"We mark the 15<sup>th</sup> anniversary of the foundation of PeptiDream this year. I saw all the objectives of the business plan I had set then in 2006, to build a substantial bio-venture on sound and profitmaking financial base and strategy, were successfully achieved in 2017 when PeptiStar was established. I also saw that now PeptiDream has fostered people with talents centering Patrick C. Reid, to whom I feel very comfortable to hand over the baton from next 10 to 20 years business perspectives. So now I believe it is a time for me to leave the business to the next generation with good grace at the conclusion of the 15<sup>th</sup> Ordinary General Meeting of Shareholders. I would like to express my cordial gratitude for your support during these years and I am very much looking forward to follow the development of PeptiDream as founding shareholder from the day of resignation onward, and to continue to dedicate myself to nurture and grow business start-ups as a second or third example of success as I did with PeptiDream." said **Kiichi Kubota, Director and Chairman of PeptiDream**.

"On behalf of everyone here at PeptiDream, we would like to sincerely thank Kiichi for all of his hard work, dedication, and leadership over the years. It has been a pleasure and privilege working with him over the years, and we wish him all the best in his future endeavors." said **Patrick C. Reid PhD, Representative Director, President and CEO of PeptiDream.** 

## <About PeptiDream Inc.>

PeptiDream Inc. is a public (Tokyo Stock Exchange 1<sup>st</sup> Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-theart highly versatile discovery platform which enables the production of highly diverse (trillions) nonstandard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.

Enquiries: PeptiDream Inc. Mie Yamazaki IR & Public Affairs - (Kanagawa) EMAIL: m-yamazaki@peptidream.com